和肽素作为精氨酸加压素的替代标志物与IgA肾病患者疾病严重程度及进展相关
该前瞻性队列纳入59例经活检证实的IgA肾病患者,检测基线血浆和肽素及尿α1微球蛋白、β2微球蛋白等标志物,随访5年。结果显示基线和肽素与α1微球蛋白、β2微球蛋白及蛋白尿相关,最高三分位组与复合肾脏结局及其各组分发生相关,且在平均动脉压、蛋白尿和eGFR之外具有预后价值。
要点
- 基线血浆和肽素与尿α1微球蛋白、β2微球蛋白及蛋白尿相关。
- 基线和肽素最高三分位组与复合肾脏结局及其各组分发生正相关。
- 在平均动脉压、蛋白尿和eGFR之外,和肽素对复合肾脏结局显示预后价值。
核心结论
- 和肽素与IgA肾病患者的疾病严重程度和预后相关,可能在已确立的风险标志物之外具有额外的预后价值。
研究设计与样本
- 前瞻性队列研究,纳入59例经活检证实的IgA肾病患者,基线检测尿α1微球蛋白、β2微球蛋白、肾损伤分子-1、中性粒细胞明胶酶相关脂质运载蛋白和总蛋白,并检测储存的基线血清样本中的血浆和肽素,随访5年。
主要发现
- IgA肾病患者中男性占72%,年龄42±13岁,平均动脉压101±12 mmHg,蛋白尿1.4(0.7-2.3)g/天,估算肾小球滤过率48±21 mL/min/1.73 m²,中位和肽素为9.4(5.3-18.4)pmol/L。
- 基线时,校正性别和估算肾小球滤过率后,和肽素与α1微球蛋白相关(标准化β=0.34,P=0.009),与β2微球蛋白相关(标准化β=0.33,P=0.01),与蛋白尿相关(标准化β=0.36,P=0.053)。
- 随访期间,基线和肽素最高三分位与复合肾脏结局的发生率正相关,也与血清肌酐加倍、终末期肾病和开始免疫抑制治疗各组分正相关。
- 在Cox回归模型中,和肽素对复合肾脏结局显示出优于平均动脉压、蛋白尿和估算肾小球滤过率的预后价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Besides its essential role for water homeostasis, arginine vasopressin (AVP) may have deleterious effects on the kidney. Copeptin, a surrogate marker for AVP, has been shown to be related to renal outcome in patients with diabetic nephropathy and polycystic kidney disease. We investigated the association of copeptin with disease severity and progression in immunoglobulin A nephropathy (IgAN). METHODS: We included a prospective cohort of 59 patients with biopsy proven IgAN. Urinary excretion of α1 microglobulin (α1m), β 2 microglobulin (β2m), kidney injury molecule-1, neutrophil gelatinase-associated lipocalin and total protein were measured at baseline. Plasma copeptin was determined from stored baseline serum samples. Cox regression was performed for the composite renal outcome defined as doubling of serum creatinine, end-stage renal disease (ESRD) or start of immunosuppressive therapy, and for the individual components during 5-year follow-up. RESULTS: In IgAN patients [male: 72%, age: 42 ± 13 years, mean arterial pressure (MAP): 101 ± 12 mmHg, proteinuria: 1.4 (0.7-2.3) g/day, estimated glomerular filtration rate (eGFR): 48 ± 21 mL/min/1.73 m 2 ] median copeptin was 9.4 (5.3-18.4) pmol/L. At baseline, copeptin was associated with α1m [standardized beta (St. β) = 0.34, P = 0.009], β2m (St. β = 0.33, P = 0.01) and proteinuria (St. β = 0.36, P = 0.053), adjusted for sex and eGFR. During follow-up, the highest tertile of baseline copeptin was positively associated with the incidence of the composite renal outcome as well as with the individual components of doubling of creatinine, ESRD and start of immunosuppressive therapy. In Cox regression models, copeptin showed prognostic value over MAP, proteinuria and eGFR for the composite renal outcome. CONCLUSIONS: Copeptin is associated with disease severity and prognosis in IgAN patients and may have additional prognostic value besides established risk markers.
引用
- Zittema D, van den Brand JA, Bakker SJ, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. Nephrol Dial Transplant. 2017. PMID: 28057871. doi:10.1093/ndt/gfw391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。